시장보고서

상품코드

1831884

건선성 관절염 치료 시장 보고서 : 약물 유형별, 유형별, 투여 경로별, 유통 채널별, 지역별(2025-2033년)

Psoriatic Arthritis Treatment Market Report by Drug Type (NSAIDs, DMARDs, Biologics, and Others), Type, Route of Administration, Distribution Channel, and Region 2025-2033

발행일: 2025년 10월 | 리서치사:

IMARC | 페이지 정보: 영문 138 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 건선성 관절염 치료 시장 규모는 2024년 105억 달러에 달했습니다. 향후 IMARC Group은 2033년에는 232억 달러에 달할 것으로 예상하며, 2025년부터 2033년까지 8.71%의 연평균 성장률(CAGR)을 기록할 것으로 예측했습니다.

건선성 관절염은 면역체계가 관절을 공격해 염증을 일으키는 자가면역질환입니다. 치료 옵션은 부종과 염증을 억제하는 내복약부터 특정 면역 체계를 표적으로 하는 생물학적 치료까지 다양합니다. 통증과 부종, 뻣뻣함의 정도에 따라 치료가 이루어집니다. 현재 주요 기업들은 질병의 진행을 막고, 통증을 줄이고, 관절을 보호하고, 운동 범위를 유지하는 새로운 치료법을 도입하고 있습니다. 이러한 방법은 근육과 관절을 강화하고 전반적인 안정성을 향상시키는 물리치료와 병행할 수 있습니다.

건선성 관절염 치료 시장 동향:

건선 질환은 건선성 관절염의 주요 위험 요인 중 하나입니다. 그 결과, 감염, 스트레스, 비만, 피부 손상, 알코올 남용, 비타민 결핍 등으로 인한 건선 질환의 유병률 증가가 시장에 긍정적인 영향을 미치는 주요 요인 중 하나입니다. 또한, 건선성 관절염은 30세에서 50세 사이에 가장 흔하게 발생하기 때문에 전 세계 성인 인구의 증가가 시장 성장에 기여하고 있습니다. 이 외에도 건선성 관절염을 앓고 있는 어린이는 안구 중층 조직을 침범하는 포도막염에 걸릴 확률이 높습니다. 이는 자녀의 건강에 대한 부모들의 관심이 높아지면서 전 세계적으로 건선성 관절염 치료에 대한 수요를 불러일으키고 있습니다. 또한, 조기 진단과 조기 치료로 심각한 손상을 예방하는 등 관절염 건선의 장점에 대한 인식이 높아지면서 시장 성장을 견인하고 있습니다. 그 외 개인의 가처분 소득 증가, 의료 시설의 개선, 개인의 건강 인식 증가 등이 심각한 증상을 치료하기 위한 새로운 건선성 관절염 치료에 대한 수요를 촉진할 것으로 예상됩니다.

본 보고서에서 다루는 주요 질문

세계 건선성 관절염 치료 시장은 지금까지 어떻게 변화해왔고, 앞으로 어떻게 변화할 것인가?
COVID-19가 건선성 관절염 치료 세계 시장에 미치는 영향은?
주요 지역 시장은?
약제 종류별 시장 현황은?
유형별 시장 분석은?
투여 경로별 시장 현황은?
유통 채널별 시장 현황은?
산업 가치사슬의 다양한 단계는 무엇인가?
업계의 주요 촉진요인과 과제는 무엇인가?
세계 건선성 관절염 치료 시장의 구조와 주요 기업은?
업계 내 경쟁은 어느 정도인가?

Psoriatic arthritis is an autoimmune disorder wherein the immune system attacks the joints and causes inflammation. Its treatment options vary from oral medications that reduce swelling and inflammation to biological therapies that target the specific immune system. It is treated as per the level of pain, swelling, and stiffness. At present, key players are introducing new treatment methods that help prevent disease progression, reduce pain, protect joints, and preserve the range of motion. These methods can be combined with physical therapy to strengthen muscles and joints and increase overall stability.

Psoriatic Arthritis Treatment Market Trends:

Psoriasis disease is one of the major risk factors for psoriatic arthritis. As a result, the increasing prevalence of psoriasis disease due to infection, stress, obesity, skin injuries, alcohol abuse, and vitamin deficiencies represents one of the primary factors influencing the market positively. Moreover, as psoriatic arthritis occurs most commonly among individuals between the ages of 30 and 50, the rising adult population worldwide is contributing to the market growth. Apart from this, children with psoriatic arthritis are more likely to develop uveitis that affects the middle layer of tissue in the eyewall. This, in confluence with the growing concerns among parents about the health of their children, is catalyzing the demand for psoriatic arthritis treatment across the globe. In addition, the rising awareness about the benefits of early diagnosis and treatment of psoriatic arthritis, such as preventing serious damages, is bolstering the market growth. Other factors, such as inflating disposable income of individuals, improvement in healthcare facilities, and the growing health awareness among individuals, are anticipated to drive the demand for novel psoriatic arthritis treatment to combat severe symptoms.

Key Market Segmentation:

Breakup by Drug Type:

NSAIDs (Nonsteroidal Anti-Inflammatory drugs)
DMARDs (Disease-Modifying Anti-Rheumatic Drugs)
Biologics
Others

Breakup by Type:

Prescription
OTC

Breakup by Route of Administration:

Injectable
Oral
Topical

Breakup by Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Breakup by Region:

North America
- United States
- Canada
Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Amgen Inc., Amneal Pharmaceuticals LLC, AstraZeneca plc, Bristol-Myers Squibb Company, Eisai Co. Ltd., Eli Lilly and Company, Johnson & Johnson Service ltd., Novartis AG, Pfizer Inc., Samsung Biologics and UCB S.A.

Key Questions Answered in This Report:

How has the global psoriatic arthritis treatment market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global psoriatic arthritis treatment market?
What are the key regional markets?
What is the breakup of the market based on the drug type?
What is the breakup of the market based on the type?
What is the breakup of the market based on the route of administration?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global psoriatic arthritis treatment market and who are the key players?
What is the degree of competition in the industry?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Psoriatic Arthritis Treatment Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Drug Type

6.1 NSAIDs (Nonsteroidal Anti-Inflammatory Drugs)
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 DMARDs (Disease-Modifying Anti-Rheumatic Drugs)
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Biologics
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast

7 Market Breakup by Type

7.1 Prescription
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 OTC
- 7.2.1 Market Trends
- 7.2.2 Market Forecast

8 Market Breakup by Route of Administration

8.1 Injectable
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Oral
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Topical
- 8.3.1 Market Trends
- 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

9.1 Hospital Pharmacies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Retail Pharmacies
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Online Pharmacies
- 9.3.1 Market Trends
- 9.3.2 Market Forecast

10 Market Breakup by Region

10.1 North America
- 10.1.1 United States
  - 10.1.1.1 Market Trends
  - 10.1.1.2 Market Forecast
- 10.1.2 Canada
  - 10.1.2.1 Market Trends
  - 10.1.2.2 Market Forecast
10.2 Asia-Pacific
- 10.2.1 China
  - 10.2.1.1 Market Trends
  - 10.2.1.2 Market Forecast
- 10.2.2 Japan
  - 10.2.2.1 Market Trends
  - 10.2.2.2 Market Forecast
- 10.2.3 India
  - 10.2.3.1 Market Trends
  - 10.2.3.2 Market Forecast
- 10.2.4 South Korea
  - 10.2.4.1 Market Trends
  - 10.2.4.2 Market Forecast
- 10.2.5 Australia
  - 10.2.5.1 Market Trends
  - 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
  - 10.2.6.1 Market Trends
  - 10.2.6.2 Market Forecast
- 10.2.7 Others
  - 10.2.7.1 Market Trends
  - 10.2.7.2 Market Forecast
10.3 Europe
- 10.3.1 Germany
  - 10.3.1.1 Market Trends
  - 10.3.1.2 Market Forecast
- 10.3.2 France
  - 10.3.2.1 Market Trends
  - 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
  - 10.3.3.1 Market Trends
  - 10.3.3.2 Market Forecast
- 10.3.4 Italy
  - 10.3.4.1 Market Trends
  - 10.3.4.2 Market Forecast
- 10.3.5 Spain
  - 10.3.5.1 Market Trends
  - 10.3.5.2 Market Forecast
- 10.3.6 Russia
  - 10.3.6.1 Market Trends
  - 10.3.6.2 Market Forecast
- 10.3.7 Others
  - 10.3.7.1 Market Trends
  - 10.3.7.2 Market Forecast
10.4 Latin America
- 10.4.1 Brazil
  - 10.4.1.1 Market Trends
  - 10.4.1.2 Market Forecast
- 10.4.2 Mexico
  - 10.4.2.1 Market Trends
  - 10.4.2.2 Market Forecast
- 10.4.3 Others
  - 10.4.3.1 Market Trends
  - 10.4.3.2 Market Forecast
10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast

11 SWOT Analysis

11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- 15.3.1 AbbVie Inc.
  - 15.3.1.1 Company Overview
  - 15.3.1.2 Product Portfolio
  - 15.3.1.3 Financials
  - 15.3.1.4 SWOT Analysis
- 15.3.2 Amgen Inc.
  - 15.3.2.1 Company Overview
  - 15.3.2.2 Product Portfolio
  - 15.3.2.3 Financials
  - 15.3.2.4 SWOT Analysis
- 15.3.3 Amneal Pharmaceuticals LLC
  - 15.3.3.1 Company Overview
  - 15.3.3.2 Product Portfolio
  - 15.3.3.3 Financials
- 15.3.4 AstraZeneca plc
  - 15.3.4.1 Company Overview
  - 15.3.4.2 Product Portfolio
  - 15.3.4.3 Financials
  - 15.3.4.4 SWOT Analysis
- 15.3.5 Bristol-Myers Squibb Company
  - 15.3.5.1 Company Overview
  - 15.3.5.2 Product Portfolio
  - 15.3.5.3 Financials
  - 15.3.5.4 SWOT Analysis
- 15.3.6 Eisai Co. Ltd.
  - 15.3.6.1 Company Overview
  - 15.3.6.2 Product Portfolio
  - 15.3.6.3 Financials
  - 15.3.6.4 SWOT Analysis
- 15.3.7 Eli Lilly and Company
  - 15.3.7.1 Company Overview
  - 15.3.7.2 Product Portfolio
  - 15.3.7.3 Financials
  - 15.3.7.4 SWOT Analysis
- 15.3.8 Johnson & Johnson Service ltd.
  - 15.3.8.1 Company Overview
  - 15.3.8.2 Product Portfolio
  - 15.3.8.3 Financials
  - 15.3.8.4 SWOT Analysis
- 15.3.9 Novartis AG
  - 15.3.9.1 Company Overview
  - 15.3.9.2 Product Portfolio
  - 15.3.9.3 Financials
  - 15.3.9.4 SWOT Analysis
- 15.3.10 Pfizer Inc.
  - 15.3.10.1 Company Overview
  - 15.3.10.2 Product Portfolio
  - 15.3.10.3 Financials
  - 15.3.10.4 SWOT Analysis
- 15.3.11 Samsung Biologics
  - 15.3.11.1 Company Overview
  - 15.3.11.2 Product Portfolio
  - 15.3.11.3 Financials
- 15.3.12 UCB S.A.
  - 15.3.12.1 Company Overview
  - 15.3.12.2 Product Portfolio
  - 15.3.12.3 Financials
  - 15.3.12.4 SWOT Analysis

건선성 관절염 치료 시장 보고서 : 약물 유형별, 유형별, 투여 경로별, 유통 채널별, 지역별(2025-2033년)

Psoriatic Arthritis Treatment Market Report by Drug Type (NSAIDs, DMARDs, Biologics, and Others), Type, Route of Administration, Distribution Channel, and Region 2025-2033

건선성 관절염 치료 시장 동향:

본 보고서에서 다루는 주요 질문

목차

제1장 서문

제2장 조사 범위와 조사 방법

제3장 주요 요약

제4장 소개

제5장 세계의 건선성 관절염 치료 시장

제6장 시장 내역 : 약물 유형별

제7장 시장 내역 : 유형별

제8장 시장 내역 : 투여 경로별

제9장 시장 내역 : 유통 채널별

제10장 시장 내역 : 지역별

제11장 SWOT 분석

제12장 밸류체인 분석

제13장 Porter's Five Forces 분석

제14장 가격 분석

제15장 경쟁 구도